Supporting Clinical Decision-Making during the SARS-CoV-2 Pandemic through a Global Research Commitment: The TERAVOLT Experience. Cancer cell Trama, A. n., Proto, C. n., Whisenant, J. G., Torri, V. n., Cortellini, A. n., Michielin, O. n., Barlesi, F. n., Dingemans, A. C., Van Meerbeeck, J. n., Pancaldi, V. n., Mazieres, J. n., Soo, R. A., Leighl, N. B., Peters, S. n., Wakelee, H. n., Horn, L. n., Hellmann, M. n., Wong, S. K., Garassino, M. C., Baena, J. n. 2020


To understand the real impact of COVID-19 on cancer patients, an entirely new data collection effort was initiated within the Thoracic Cancers International COVID-19 Collaboration (TERAVOLT). TERAVOLT reported high mortality related to COVID-19 infection in thoracic cancer patients and identified several negative prognostic factors. In this commentary, we discuss the importance and limits of patient registries to support decision-making in thoracic cancer during the SARS-CoV-2 pandemic.

View details for DOI 10.1016/j.ccell.2020.10.002

View details for PubMedID 33091381

View details for PubMedCentralID PMC7534826